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A chimeric gene, MSP-Fu24, was constructed by genetically coupling immunodominant, conserved regions of
the two leading malaria vaccine candidates, Plasmodium falciparum merozoite surface protein 1 (C-terminal
19-kDa region [PfMSP-119]) and merozoite surface protein 3 (11-kDa conserved region [PfMSP-311]). The
recombinant MSP-Fu24 protein was produced in Escherichia coli cells and purified to homogeneity by a two-step
purification process with a yield of 30 mg/liter. Analyses of conformational properties of MSP-Fu24 using
PfMSP-119-specific monoclonal antibody showed that the conformational epitopes of PfMSP-119 that may be
critical for the generation of the antiparasitic immune response remained intact in the fusion protein.
Recombinant MSP-Fu24 was highly immunogenic in mice and in rabbits when formulated with two different
human-compatible adjuvants and induced an immune response against both PfMSP-119 and PfMSP-311.
Purified anti-MSP-Fu24 antibodies showed invasion inhibition of P. falciparum 3D7 and FCR parasites, and
this effect was found to be dependent on antibodies specific for the PfMSP-119 component. The protective
potential of MSP-Fu24 was demonstrated by in vitro parasite growth inhibition using an antibody-dependent
cell inhibition (ADCI) assay with anti-MSP-Fu24 antibodies. Overall, the antiparasitic activity was mediated by
a combination of growth-inhibitory antibodies generated by both the PfMSP-119 and PfMSP-311 components
of the MSP-Fu24 protein. The antiparasitic activities elicited by anti-MSP-Fu24 antibodies were comparable to
those elicited by antibodies generated with immunization with a physical mixture of two component antigens,
PfMSP-119 and PfMSP-311. The fusion protein induces a protective immune response with human-compatible
adjuvants and may form a part of a multicomponent malaria vaccine.
Malaria is among the major parasitic diseases in tropical and
subtropical countries. With as many as 300 to 500 million new
cases each year, malaria accounts for the death of over 2
million people globally each year, and most are children (41).
Among the four species of Plasmodium that infect humans, the
most threatening is Plasmodium falciparum. The extensive
spread of drug-resistant P. falciparum strains as well as the
insecticide-resistant mosquito necessitates the development of
a malaria vaccine on an urgent basis. Collectively, the major
objective of the ongoing vaccine effort in this field is to develop
a multistage, multivalent vaccine against P. falciparum (34).
The blood-stage cycle of the parasite is responsible for ma-
laria pathogenesis. Intervention at this stage of the parasite’s
development through vaccination is likely to reduce malaria-
related clinical symptoms. As a major interface between host
and pathogen, the merozoite surface is an obvious target for
the development of a malaria vaccine. A number of potential
vaccine candidate antigens identified so far are located on or
associated with the surface of the merozoite or in apical or-
ganelles. These include merozoite surface protein 1 (MSP-1),
MSP-2, MSP-3, MSP-4, MSP-5, MSP-8, RAP1/2, AMA-1, and
EBA-175, which are implicated in the process of merozoite
invasion of the erythrocyte (23).
MSP-1 is one of the most extensively studied proteins of P.
falciparum (18). It is synthesized as a 200-kDa precursor and
then processed in two steps: the primary processing step pro-
duces a complex of four fragments that are present on the
merozoite surface, and the secondary processing step at inva-
sion results in the shedding of the complex from the surface,
except for the C-terminal 19-kDa domain (MSP-119), which
remains anchored to the parasite surface by a glycosylphos-
phatidylinositol (GPI) moiety (2). The C-terminal 19-kDa frag-
ment of MSP-1 is well conserved among P. falciparum isolates
and contains two epidermal growth factor (EGF)-like domains
that play a role in merozoite invasion. Substantial data from
studies with P. falciparum MSP-1 and in vivo immunization
studies of mice with Plasmodium yoelii and Plasmodium
chabaudi indicate that the protective immune responses are
directed against the C-terminal 19-kDa domain (10, 12, 15, 20,
27, 35). The inhibition of MSP-1 processing by conformation-
specific antibodies (Abs) was previously proposed to be one of
the possible mechanism for the inhibition of merozoite inva-
sion (1).
Another merozoite surface protein, MSP-3, was also shown
to be the target of the protective immune responses in humans
(29). The PfMSP-3 protein contains three blocks of four tan-
dem heptad repeats based on the AXXAXX motif at the N
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terminus, a glutamic acid-rich domain, and a putative leucine
zipper sequence at the C terminus (25). Although a clear
surface localization of PfMSP-3 is known, it lacks any trans-
membrane domain or glycosylphosphatidylinositol (GPI) an-
chor site (24, 25) and is therefore considered to be loosely
associated with the merozoite surface by interactions with
other merozoite surface proteins. PfMSP-3 was identified as a
candidate vaccine antigen by an antibody-dependent cellular
inhibition (ADCI) assay using human immune sera (28). The
potential of PfMSP-3 as a vaccine candidate was further illus-
trated by ADCI using mice antibodies and was further con-
firmed by the suppression of P. falciparum growth in an immu-
nocompromised mouse after the passive transfer of human
antibodies purified on MSP-3 peptides together with human
monocytes (28, 40, 42). The immunization of Aotus and Saimiri
monkeys with recombinant PfMSP-3 or its fragments provided
protection against parasite challenge (6, 16). A 70-amino-acid-
long conserved domain of PfMSP-3, referred to here as the
PfMSP-311 region, was identified as the target of protective
antibodies in human immune responses (40). The presence of
high titers of cytophilic antibodies, IgG3, against this con-
served region of MSP-3 has been correlated with protection
against the parasite. In addition, immunization of humans with
a synthetic peptide corresponding to this region was previously
shown to induce antiparasitic antibodies that suppress parasite
growth in an ADCI assay (11).
It is generally believed that a combination vaccine for ma-
laria is likely to be more effective than vaccines based on a single
antigen, and attempts are being made to develop a malaria vac-
cine by using a mixture of more than one antigen or by com-
bining immunologically relevant proteins of the target antigens
as fusion proteins (31, 43, 45). In the present study, we have
constructed a fusion chimera (MSP-Fu24) consisting of PfMSP-
119 and PfMSP-311 and produced the corresponding recombi-
nant MSP-Fu24 protein in Escherichia coli cells. The two indi-
vidual components, PfMSP-119 and PfMSP-311, were also
expressed and purified separately; the immunological proper-
ties of MSP-Fu24 were compared with a physical mixture of the
two individual components. MSP-Fu24 retained the native con-
formation of the PfMSP-119 component and was highly immu-
nogenic in small animals. The anti-MSP-Fu24 antibodies inhib-
ited parasite invasion into host red blood cells (RBCs) and also
inhibited parasite growth in a monocyte-dependent manner,
suggesting the potential of the fusion protein as a malaria
vaccine candidate.
MATERIALS AND METHODS
Construction of plasmids expressing PfMSP-311, PfMSP-119, and MSP-Fu24.
To design a synthetic gene corresponding to the C-terminal 19-kDa fragment of
PfMSP-1, the amino acid sequence of PfMSP-119 corresponding to residues 1526
to 1619 of the P. falciparum Welcome strain (GenBank accession no. P04933)
was back-translated to the nucleotide sequence based on the E. coli codon
frequency table (available at http://www.kazusa.or.jp/codon). This synthetic gene
was used as a template to amplify PfMSP-119 with the NcoI-XhoI site with the
following primer set: forward primer 5-GTG ACA CCA TGG GTA ACA TTT
CTC AGC ATC AGT G-3 and reverse primer 5-GCC CTC GAG TTA GTG
GTG GTG GTG GTG GTG GGA ACT GCA GAA AAT ACC ATC-3. The
amplified product was cloned into the NcoI and XhoI sites of pET28a(), a
kanamycin-based vector (Novagen), in frame with the coding sequence of the
6His tag at its C terminus, to obtain the pET28a-PfMSP-119 construct.
The conserved 11-kDa fragment of PfMSP-3 corresponding to 70 amino acids
(163 to 230 amino acids) was amplified from a PfMSP-3 synthetic gene with the
following set of primers: forward primer 5-GGC GGC CAT GGC AAA GAA
TGC TTA CGA AAA GGC C-3 and reverse primer 5-GGC CTC GAG TTA
GTG GTG GTG GTG GTG GTG GTC GTT TTC CTT AGA GAT GTT
TTC-3. The amplified product was cloned into the NcoI and XhoI sites of
pET28a, in frame with the coding sequence of the 6His tag at its C terminus,
to obtain the pET28a-PfMSP-311 construct.
To generate a fusion construct consisting of PfMSP-311 and PfMSP-119, the
11-kDa fragment of PfMSP-3 was amplified again with different sets of primers:
forward primer 5-GGC GGC CAT GGC AAA GAA TGC TTA CGA AAA
GGC C-3 and reverse primer 5-GCC GCC CAT GGC GTC GTT TTC CTT
AGA GAT GTT TTC-3. The amplified PCR product was purified and digested
with NcoI. The excised fragment was cloned into the NcoI site of pET28a-
PfMSP-119 to generate the pET28a-MSP-Fu24 construct.
All constructs were sequenced from both ends to confirm the orientation and
sequence of the inserts and transformed into E. coli BLR(DE3) cells (Novagen)
for the expression of recombinant proteins with 6His tags.
Expression and purification of recombinant proteins. E. coli BLR(DE3) cells
containing recombinant plasmids pET28a-PfMSP-119, pET28a-PfMSP-311, and
pET28a-MSP-Fu24 were grown in Luria broth containing kanamycin (30 g/ml)
at 37°C until an optical density at 600 nm (OD600) of 0.6 to 0.7 was reached. The
expressions of the respective recombinant proteins were induced with 1 mM
isopropyl--D-thiogalactopyranoside (IPTG) for 3 h at 37°C, and the expressed
proteins were analyzed and localized by sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE) and Western blotting of the soluble and
insoluble fractions of the E. coli cells after disruption.
For the purification of recombinant MSP-Fu24 and PfMSP-119, the E. coli cell
pellets from the respective 6-liter shake flask cultures were washed with phosphate-
buffed saline (PBS) and resuspended in lysis buffer (20 mM Tris-HCl [pH 8.0],
500 mM NaCl, 10 mM imidazole, 1% Triton X-100, 25 mg liter1 lysozyme, 5
mM benzamidine HCl). The bacterial cells were lysed on ice by sonication, and
the lysate was centrifuged at 12,000 rpm for 45 min at 4°C. The clarified super-
natant was loaded onto a column containing precharged streamline chelating
matrix (GE Healthcare). The column was subsequently washed with 10 column
volumes of equilibration buffer (20 mM Tris-HCl [pH 8.0], 500 mM NaCl, 10 mM
imidazole), followed by 10 column volumes each of wash buffer 1 (20 mM Tris-HCl [pH
8.0], 500 mM NaCl, 40 mM imidazole) and wash buffer 2 (20 mM Tris-HCl [pH
8.0], 10 mM NaCl, 40 mM imidazole). Bound protein was eluted with a linear
gradient of imidazole (40 mM to 1 M) in 20 mM Tris–10 mM NaCl (pH 8.0)
buffer. The eluted fractions were analyzed by SDS-PAGE, and fractions con-
taining the recombinant protein were pooled. The pooled protein was further
purified by anion-exchange chromatography on a column of Q-Sepharose resin
(GE Healthcare) equilibrated with equilibration buffer (20 mM Tris-HCl [pH
8.0], 10 mM NaCl). The bound proteins were eluted with a linear gradient of
NaCl (10 mM to 1 M) in Tris-HCl buffer (pH 8.0). Eluates were analyzed by
SDS-PAGE, fractions containing a single protein band of MSP-Fu24 or PfMSP-
119 were pooled, and the protein concentration was determined by a bicincho-
ninic acid assay (BCA).
For the purification of PfMSP-311, the cell pellet from the 6-liter shake flask
culture was lysed by sonication, and the inclusion bodies (IBs) were collected by
centrifugation at 12,000 rpm. The IB pellet was resuspended in solubilization
buffer (20 mM Tris-HCl [pH 8.0], 500 mM NaCl, 10 mM imidazole, 8 M urea)
and kept for 12 to 15 h under stirring at room temperature (RT). The solubilized
IBs were centrifuged at 12,000 rpm for 45 min at room temperature, and clarified
supernatant was loaded onto a column containing precharged streamline che-
lating matrix (GE Healthcare). The column was sequentially washed with 10
column volumes of equilibration buffer (20 mM Tris-HCl [pH 8.0], 500 mM
NaCl, 10 mM imidazole, 8 M urea), wash buffer 1 containing 8 M urea, and wash
buffer 2 containing 8 M urea. The bound protein was eluted by a linear gradient
of imidazole (40 mM to 500 mM) in elution buffer (20 mM Tris-HCl [pH 8.0], 10
mM NaCl, 8 M urea). The fractions were analyzed by SDS-PAGE, and those
fractions containing the PfMSP-311 protein were pooled and dialyzed sequen-
tially against 6 M, 4 M, and 2 M urea in dialysis buffer (20 mM Tris-HCl [pH
8.0]), followed by a final change in 20 mM Tris–10 mM NaCl (pH 8.0). Dialyzed
PfMSP-311 was further purified by anion-exchange chromatography by using the
Q Sepharose matrix, as mentioned above.
The homogeneity of purified MSP-Fu24, PfMSP-311, and PfMSP-119 was as-
sessed by SDS-PAGE under reducing and nonreducing conditions, on an ana-
lytical gel permeation chromatography column, and by reverse-phase chroma-
tography on an analytical C8 column (Supelcosil; 5 by 4.9 cm, 5 m). Endotoxin
contents in the protein samples were estimated by using a Limulus amebocyte
lysate (LAL) gel clot assay (Charles River Endosafe), and host cell protein
contamination was estimated by immunoblotting as well as by enzyme-linked
immunosorbent assay (ELISA) using anti-E. coli antibodies (Cygnus Technolo-
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gies). The reactivity of the recombinant proteins with monoclonal and polyclonal
antibodies was analyzed by immunoblotting according to standard protocols.
Briefly, the recombinant proteins were separated by SDS-PAGE under reducing
or nonreducing conditions and blotted onto a nitrocellulose membrane, followed
by the blocking of the membrane using 5% nonfat milk in PBS (pH 7.4). The
blots were sequentially incubated with the respective monoclonal or polyclonal
antibodies in PBS (pH 7.4) containing 0.5% milk and 0.05% Tween 20, followed
by the respective horseradish peroxidase-conjugated secondary antibody, after
prior washing with PBS containing 0.05% Tween 20 (PBS-T). The protein bands
were detected after developing the reaction mixture with 3,3-diaminobenzidine
tetrahydrochloride (DAB) in PBS and hydrogen peroxide (H2O2).
Immunization of mice and rabbits with recombinant antigens formulated with
Freund’s adjuvant (IFA), alum, and Montanide ISA720. Three different adju-
vants used in the immunization study were Freund’s complete adjuvant (CFA)
and Freund’s incomplete adjuvant (Sigma), alum (Alhydrogel; Superfos, Den-
mark), and Montanide ISA 720 (Seppic Inc., France). Vaccine formulations were
prepared with the individual antigen or their mixture according to the manufac-
turers’ instructions. Groups of five BALB/c mice 4 to 6 weeks of age were
immunized intramuscularly with 25 g of the individual antigens (MSP-Fu24,
PfMSP-311, or PfMSP-119) or a mixture of PfMSP-311 and PfMSP-119 (25 g
each) in each of the adjuvant formulations. Control groups received only PBS
mixed with adjuvants. Immunized animals were given booster doses with the
respective formulations on days 28 and 56 and were bled on days 0, 14, 42, 55,
and 70 after the first immunization. Four groups of two New Zealand White
rabbits were immunized intradermally with 200 g of MSP-Fu24 or with a
mixture of PfMSP-311 and PfMSP-119 (200 g each) emulsified with either
Montanide ISA720 or alum. Two booster immunizations were carried out intra-
muscularly on day 28 and day 56 by using the respective adjuvant formulations,
and mice were bled on day 70 after the first immunization. The sera obtained
were used for immunoassay and IgG purification. For the duration of this study,
mice and rabbits were housed and used strictly in accordance with the guidelines
set by the National Institutes of Health in 1985, and the study was approved by
the institutional animal ethics committee of the International Centre for Genetic
Engineering and Biotechnology (ICGEB).
IgG purification from rabbit and mouse sera. Total IgG was purified from sera
obtained from immunized groups of mice and rabbits as well as from the control
groups by using a protein G-Sepharose column (Pharmacia) according to the
manufacturer’s recommendations. Briefly, a serum sample, after equal dilution
with binding buffer (20 mM sodium phosphate buffer [pH 7.0]), was loaded onto
a protein G-Sepharose column preequilibrated with binding buffer. The column
was washed with 10 column volumes of the binding buffer. The bound IgG was
eluted with 0.2 M glycine-HCl (pH 3.0), and eluted fractions were analyzed by
SDS-PAGE. The fractions containing purified IgGs were pooled and dialyzed
against PBS.
Human immune sera from a region where malaria is endemic. Forty-two
human sera were collected from healthy individuals residing in an area where P.
falciparum is endemic (Orissa, India); these individuals were without any blood-
stage infection at the time of collection and had no recent history of any malaria
infection. Consent from these individuals and approval from the Human Vol-
unteers Research Ethical Committee of the International Centre for Genetic
Engineering and Biotechnology were obtained prior to the study. Serum samples
were also collected from individuals who had no known history of malaria and
had never visited an area where malaria is endemic.
ELISA and competitive ELISA. Antibody responses in mice as well as the
reactivity of human sera and monoclonal antibodies (MAbs) (12.10, 2F10, and
5.2) with the respective antigens were evaluated by ELISA. All ELISAs were
carried out using a 100-l reaction mixture volume. Briefly, 96-well microplates
(Dynatech) were coated with 100 ng of the antigens (MSP-Fu24, PfMSP-311, or
PfMSP-119; antigen concentration, 1 g/ml) diluted in 0.06 M carbonate-bicar-
bonate buffer (pH 9.6) per well. Plates were washed with 1 PBS containing
0.05% Tween 20 (PBS-T), and the wells were blocked with 5% low-fat milk in
PBS (pH 7.2) for 1 h at room temperature. Antigen-coated wells were sequen-
tially incubated with serial dilutions of immune sera from mouse or rabbit and
then with enzyme-labeled secondary antibody (horseradish peroxidase-labeled
anti-mouse or anti-human immunoglobulin [IgG]). In between these incubations,
the plates were washed with PBS-T. The enzyme reaction mixture was developed
with o-phenylenediamine dihydrochloride–H2O2 in a citrate phosphate buffer
(pH 5.0), the reaction was stopped with 8 M H2SO4, and the OD was recorded
at 490 nm by use of a microplate reader (Molecular Devices). An OD cutoff of
0.1 (mean plus 2 standard deviations [SDs]) was selected for antibody titer
determinations. To coat the reduced/denatured protein, SDS and -mercapto-
ethanol were added to the protein solution to final concentrations of 1% (vol/vol)
and 5% (vol/vol), respectively, kept in boiling water for 5 min, and coated into
96-well microplates at a concentration of 100 ng/well.
To detect the reactivities of MSP-Fu24, PfMSp-119, and PfMSP-311 with anti-
PfMSP-1 conformation-specific monoclonal antibodies, ELISA was carried out
by using MAb 12.10 and MAb 5.2 (62.5 ng/ml) under nonreducing and reducing
conditions as described above. The assay for the reactivity of each of the recom-
binant proteins with anti-penta-His antibody (dilution, 1:1,000; Qiagen) was
carried out in parallel as a positive control to ascertain equal amounts of coating
of the antigens under reduced and nonreduced conditions. To detect subclasses
of IgG in sera of mice immunized with MSP-Fu24 or with a mixture of PfMSP-119
and PfMSP-311, ELISA was performed as described above by using immunized
mouse sera (1:10,000 dilutions); MSP-Fu24 as a capture antigen; secondary goat
antibodies specific for mouse IgG1, IgG2a, IgG2b, and IgG3 (Sigma) at dilutions
of 1:1,000; and horseradish peroxidase (HRP)-linked tertiary anti-goat antibod-
ies (Sigma). The statistical significance of the results was determined by use of an
unpaired Student’s t test.
A competitive ELISA was carried out to assess the efficacy of purified anti-
MSP-Fu24 antibodies to competitively block the binding of anti-PfMSP-119
MAbs. For this, wells of a microtiter plate were coated with 100 ng of the
PfMSP-119 protein (100 l of antigen at a concentration of 1 g/ml) as described
above. These wells were incubated with serial dilutions of the purified anti-MSP-
Fu24 rabbit antibodies (2.5 g/ml to 1.2 ng/ml) for 2 h at 37°C. After washing with
PBS-T, the wells were incubated with 6.25 ng of mouse MAb 5.2 or 12.10 (100-l
solution in 1 PBS at a concentration of 62.5 ng/ml) for 2 h at 37°C. The plates
were washed, and the binding of the MAbs was detected with anti-mouse IgG
conjugated to horseradish peroxidase. The reactivity of PfMSP-119 with MAbs
after a primary incubation with anti-MSP-Fu24 antibodies was compared with the
reactivity without any incubation.
Immunofluorescence assay. Antibodies to the recombinant proteins were
tested for their reactivity with native parasite proteins by an immunofluorescence
assay (IFA). The assay was performed essentially as described previously (36,
46). Briefly, multispot parasite slides were made from P. falciparum (3D7) cul-
tures, air dried, fixed with a mixture of acetone-methanol (9:1), and then blocked
in blocking buffer (10% fetal calf serum [FCS] in PBS) for 1 h at 37°C. Slides
were washed and incubated for 1 h with purified IgGs against each of the
antigens, appropriately diluted in blocking buffer, and kept in a sealed humid
chamber for 2 h at 37°C. Slides were washed with PBS-T and subsequently
incubated with anti-mouse and anti-rabbit secondary antibodies conjugated to
fluorescence dye (fluorescein isothiocyanate [FITC] or Cy-3; dilution, 1:250) for
1 h at room temperature in the dark. Later, the washed slides were stained with
DAPI (4,6-diamidino-2-phenylindole) at a concentration of 2 g/ml, followed
by two washes with PBS-T and one wash with PBS. The washed slides were then
mounted with a coverslip in the presence of Antifade mounting reagent (Bio-
Rad) and were viewed by using a Nikon fluorescence microscope (SE300) with
a 100 oil immersion objective.
Lymphoproliferative cellular responses and cytokine analysis. Groups of
BALB/c mice were immunized with the recombinant proteins formulated in
Montanide ISA720 or alum as described above. Fourteen days later, spleens of
two mice from each immunized group were isolated, and single-cell suspensions
were prepared from them. Cells were plated at 5  106 cells/ml in a final volume
of 200 l per well in 96-well flat-bottom plates containing RPMI 1640 medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 55 M 2-mer-
captoethanol, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 100
U of penicillin-streptomycin/ml. Cells were cultured in the presence or absence
of a graded concentration of homologous antigen (4 days) and concanavalin A (2
days) in a humidified atmosphere with 5% CO2 at 37°C. Splenocytes were
pulse-labeled with 1 Ci per well of [3H]thymidine (Amersham Pharmacia Bio-
tech) per well and harvested onto glass fiber filters by using a PHD cell harvester
(Cambridge Technology, Cambridge, MA) 16 h later. The [3H]thymidine incor-
poration was determined by -emission liquid scintillation spectroscopy (Beta-
plate; Pharmacia, Sweden). The geometric mean of the counts per minute for
each set of triplicate wells was calculated, and the stimulation indices were
calculated as the counts per minute for the test antigen divided by the counts per
minute for the control. The statistical significance of the results was determined
by use of a Student’s t test.
For determinations of cytokine production, 106 splenocytes were cultured in a
volume of 200 l in 96-well flat-bottom plates in the presence or absence of an
antigen. Culture supernatants were collected after 60 h for gamma interferon
(IFN-) analysis. IFN- was measured by using a murine cytokine immunoassay
kit (Duo Set ELISA developmental system; R&D Systems, Minneapolis, MN)
according to the procedure recommended by the manufacturer.
Parasite culture and invasion inhibition assay. P. falciparum parasite strains
3D7 and FCR were cultured by using methods described previously by Trager
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and Jensen (44). Parasite cultures were maintained under mixed gas (5% CO2,
5% O2, and 90% N2) at 37°C in O erythrocytes and RPMI 1640 medium
supplemented with 10% O human sera, 0.2% sodium bicarbonate, 0.2% glu-
cose, and gentamicin (10 g/ml). P. falciparum cultures were synchronized by
sorbitol treatment (22).
Invasion inhibition assays were performed as described previously (36, 46).
Briefly, ring-stage malaria parasites were synchronized with sorbitol lysis and
allowed to mature through to the schizont stage. Hematocrit and parasitemia
were adjusted to 2% and 0.5%, respectively. Purified IgG from rabbit sera
(preimmune and immune) was added to the parasite culture in 96-well plates at
final concentrations of 0.5, 0.25, and 0.125 mg/ml. Cultures were incubated at
37°C in a mixed-gas (5% CO2, 5% O2, and 90% N2) cabinet for 26 h to allow for
schizont rupture and merozoite invasion. These assays were performed in trip-
licate. For microscopic analysis, smears were made from triplicate wells and
stained with Giemsa stain, and the numbers of ring-stage parasites per 5,000
RBCs were determined for each well. The percent inhibition of the parasite
invasion was calculated using the following formula: percent inhibition 	 1 
[(percent invasion of purified IgG from immune sera)/(percent invasion of
purified IgG from preimmune sera)]  100.
ADCI assay. The antibody-dependent cell inhibition (ADCI) assay was carried
out by using purified IgG from mouse sera according to a procedure described
previously by Oeuvray et al. (28). Briefly, human monocytes were purified from
blood samples of healthy donors by using CD14 (monocyte/macrophage) mi-
crobeads (Miltenyi Biotech) according to the manufacturer’s protocol. The study
was approved by the Human Volunteers Research Ethical Committee of the
International Centre for Genetic Engineering and Biotechnology prior to the
study. Tightly synchronized P. falciparum 3D7 schizont-stage parasites (0.5%
parasitemia and 1% hematocrit) were cocultured in a 96-well flat-bottom micro-
culture plate with adherent human monocytes (2  106 monocytes) in complete
medium (RPMI medium containing 10% human sera). Purified antibodies at a
concentration of 50 g/ml were added to these cultures and incubated at 37°C for
96 h in a mixed-gas environment (5% O2, 5% CO2, and 90% N2). After 48 and
72 h of growth, 50 l of complete medium was added to each well. After 96 h of
growth, parasitemia was estimated for a thin Giemsa-stained smear of RBCs
from each well by counting parasitized erythrocytes in more than 10,000 eryth-
rocytes. Control wells consisted of (i) parasite alone, (ii) parasite and control IgG
(purified from naïve mouse sera), (iii) parasites and monocytes, (iv) parasites and
purified IgG without monocytes, and (v) parasites, control IgG, and monocytes.
The specific growth inhibition index (SGI) was calculated as follows: 1  [(per-
cent parasitemia with monocytes and test antibodies/percent parasitemia with
test antibodies)/(percent parasitemia with monocytes and control IgG/percent
parasitemia with control IgG)]  100.
Depletion of antigen-specific antibodies and reversal of invasion/growth inhi-
bition. Antibodies specific to MSP-Fu24, PfMSP-119, and PfMSP-311 were de-
pleted from total antibodies purified from rabbit/mouse sera by using the re-
spective recombinant antigens. Briefly, purified IgGs from rabbit or mouse sera
(0.25 mg/ml and 0.05 mg/ml, respectively) of the MSP-Fu24–Montanide ISA720
groups were mixed with the recombinant antigen (MSP-Fu24, PfMSP119, or
PfMSP-311) at different final concentrations (0.025 mg/ml, 0.05 mg/ml, or 0.1
mg/ml for rabbit antibodies and 0.05 mg/ml for mouse antibodies) and incubated
at RT for 2 h. This antigen-antibody mix was passed three times through a 1-ml
Hi-Trap Ni-nitrilotriacetic acid (NTA) column (GE Healthcare) preequilibrated
with 20 mM Tris-HCl (pH 8.0) to remove the protein-antibody complexes, and
the flowthrough was collected, concentrated, and dialyzed against incomplete
RPMI (iRPMI) medium. The respective antigen-depleted IgGs were used sub-
sequently for invasion inhibition or ADCI assays as described above. The growth
inhibition (invasion inhibition or ADCI) by depleted antibodies was compared
with that by antibodies without any depletion. Recombinant P. falciparum histi-
dine-rich protein 2 (PfHRP-2) was used for antibody depletion as a negative
control for these experiments.
RESULTS
Expression of MSP-Fu24, PfMSP-119, and PfMSP-311 in E.
coli and purification of recombinant proteins. Cloned PfMSP-
119 and PfMSP-311 gene sequences were genetically coupled to
generate MSP-Fu24, a chimeric gene construct, in the pET28a

vector (Fig. 1A and B), and the corresponding recombinant
protein was expressed in E. coli BLR(DE3) cells. For compar-
ison, the individual PfMSP-119 and PfMSP-311 fragments were
also cloned into the pET28a vector and expressed in E. coli
BLR(DE3) cells. The MSP-Fu24 protein was expressed as a
soluble protein, and its expression level of MSP-Fu24 was two-
to three-fold higher than the expression of individual PfMSP-
119 and PfMSP-311 proteins under similar conditions. PfMSP-
119 was also expressed as a soluble protein in the cytosolic
fraction, whereas PfMSP-311 was expressed as an insoluble
protein and aggregated in the inclusion bodies (IBs) of E. coli
cells.
MSP-Fu24 and PfMSP-119 were purified to homogeneity
from soluble fractions by a combination of metal affinity and
ion-exchange chromatography. These purified recombinant
proteins showed apparent mobilities of 24 kDa and 19
kDa, respectively, on SDS-PAGE gels (Fig. 1C and F). Re-
verse-phase high-performance liquid chromatography (RP-HPLC)
and gel permeation chromatography analyses suggested that
the purified MSP-Fu24 protein was 
98.0% pure and was in a
monomeric form (Fig. 1E). Recombinant PfMSP-311 was pu-
rified to homogeneity from the inclusion body fraction and
refolded; it moved as a single band at 11.0 kDa under both
reducing and nonreducing conditions on SDS-PAGE gels (Fig.
1G). The three purified proteins (MSP-Fu24, PfMSP-119, and
PfMSP-311) eluted as monomers by gel permeation chroma-
tography (see Fig. S1 in the supplemental material). The final
yields for MSP-Fu24, PfMSP-119, and PfMSP-311 were 30.0
mg/liter, 15.0 mg/liter, and 10.0 mg/liter, respectively. The final
preparations of MSP-Fu24, PfMSP-119, and PfMSP-311 con-
tained less than 12.5, 0.25, and 5.0 endotoxin units (EU) per 25
g of protein, respectively. Host cell proteins were not ob-
served in any of the protein samples, as determined by an
ELISA and Western blot analysis.
Immunological characterization of the fusion chimera. The
conformational integrity of the PfMSP-119 component in MSP-
Fu24 was assessed by its reactivity with conformation-specific
PfMSP-119 monoclonal antibodies (MAbs 5.2 and 12.10) by
immunoblotting. MSP-Fu24 also showed a strong reactivity
with MAb 5.2 by immunoblotting (Fig. 1D), as in the case of
PfMSP-119. ELISA was also carried out to determine the re-
activities of the recombinant proteins (MSP-Fu24, PfMSP-119,
and PfMSP311) with MAbs. ELISA showed that purified MSP-
Fu24 and PfMSP-119 reacted strongly with monoclonal anti-
bodies 5.2 and 12.10, which are specific for disulfide-dependent
conformational epitopes of native PfMSP-119 (Fig. 2). The
reactivities of MSP-Fu24 and PfMSP-119 with these MAbs de-
clined considerably under denatured conditions, whereas the
reactivities of MSP-Fu24, PfMSP-119, and PfMSP-311 with anti-
penta-His antibody under native and denatured conditions
were found to be similar in a parallel experiment that ascer-
tained the equal coating of the antigens in both cases (Fig. 2).
However, there was no reactivity of PfMSP-311 with any of the
anti-MSP-1 MAbs under both native and reduced/denatured
conditions. MSP-Fu24 was also recognized by polyclonal anti-
body raised against PfMSP-119 and PfMSP-311 (data not shown).
The recognition of MSP-Fu24 by human immune sera from
a region where malaria is endemic was assessed by ELISA and
compared with the reactivities of PfMSP-119 and PfMSP-311.
Thirty-two out of 44 sera (73%) showed reactivity with MSP-
Fu24. Sera that showed reactivity with both PfMSP-311 and PfMSP-
119 or with either of the two antigens also showed reactivity with
MSP-Fu24. Sera from control individuals showed no reactivity with
any of the antigens (see Fig. S2 in the supplemental material).
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Immunogenicity of MSP-Fu24 and mixture of its individual
components. The immunogenicity of MSP-Fu24, formulated
with three different adjuvants (CFA/IFA, Montanide ISA 720,
and alum) was evaluated by using BALB/c mice. In parallel
sets of experiments, groups of BALB/c mice were immunized
separately with each of the individual components (PfMSP-119
and PfMSP-311) as well as with their mixture for comparisons
of immune responses. Antigen-specific antibodies were de-
tected for each group after primary immunization, and anti-
body levels increased with each subsequent immunization. In
all groups, antibody titers reached a peak after the second boost
of immunization (data not shown).
As shown in Fig. 3, immunization with MSP-Fu24 induced
antibodies recognizing both PfMSP-119 and PfMSP311. Immu-
nization with MSP-Fu24 or with the physical mixture of the two
component antigens elicited antibodies recognizing both of the
components in all the adjuvant groups. The antibody titers
elicited for each of the component antigens in MSP-Fu24- and
in mixture-immunized groups were comparable to the titer
value elicited by the respective single-antigen-formulation
group. MSP-Fu24 induced high antibody titers in rabbits when
formulated with two human-compatible adjuvants, Montanide
ISA720 or alum (end point titers of 3.5  105 and 16.0 
105, respectively). The mixture of the two antigens also induced
FIG. 1. Design and expression of the chimeric protein MSP-Fu24. (A) Schematic diagram of P. falciparum MSP-1 (PfMSP-1) and PfMSP-3
showing the locations of the MSP-119 and MSP-311 regions. The conserved (hatched), semiconserved (filled), and variable (open) sequence blocks
of PfMSP-1 are marked. The signal sequences (SS), heptad repeat regions (HI to HIII), glutamic acid-rich region, and leucine zipper region (LZ
region) of PfMSP-3 are also marked. (B) Schematic diagram of MSP-Fu24 consisting of MSP-119 and MSP-311. (C to E) Expression and purification
of recombinant MSP-Fu24. (C) Coomassie blue-stained SDS-PAGE gel showing purified recombinant MSP-Fu24 under reducing (with dithio-
threitol [DTT]) and nonreducing (DTT) conditions. (D) Western blot analysis of MSP-Fu24 under reducing (DTT) and nonreducing (DTT)
conditions using MAb 5.2. (E) RP-HPLC profile of purified MSP-Fu24 that eluted as a single sharp peak. (F) Coomassie blue-stained SDS-PAGE
gel showing purified recombinant MSP-119 under reducing (DTT) and nonreducing (DTT) conditions. (G) Coomassie blue-stained SDS-
PAGE gel showing purified recombinant MSP-311 under reducing (DTT) and nonreducing (DTT) conditions. M, molecular mass marker.
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nearly similar levels of antibody titers when immunized in
formulations with Montanide ISA720 or alum (end point titers
of 19.3  105 and 9.4  105, respectively).
The IgG profiles between immunization groups for different
adjuvant formulations were compared. The MSP-Fu24-Mon-
tanide and mixture-Montanide groups showed similar levels
(P 
 0.05) of IgG subtypes. However, the mixture-alum im-
munization groups showed low levels of all the isotypes com-
pared to the MSP-Fu24-alum group (see Fig. S3 in the supple-
mental material).
MSP-Fu24, PfMSP-311, and PfMSP-119 induce T-cell re-
sponses in immunized mice. T-cell responses of mice immu-
nized with MSP-Fu24, PfMSP-119, PfMSP311, and a mixture of
the individual antigens were determined. Table S1 in the sup-
plemental material summarizes the cellular responses induced
upon immunization with different formulations of MSP-Fu24,
PfMSP-119, PfMSP311, and the mixture in BALB/c mice. Com-
pared to the adjuvant control, MSP-Fu24, PfMSP-119, PfMSP311,
and mixture formulations induced significant proliferation
(P 
 0.05). However, there was variation in the proliferative
responses depending upon the adjuvant (see Table S1 in the
supplemental material). Splenocytes from alum groups showed
significantly lower (P 
 0.05) proliferation than the corre-
sponding Montanide groups. After stimulation with any of
these antigens, MSP-Fu24, PfMSP-311, and PfMSP-119, the
splenocytes of the MSP-Fu24 immunization group showed sig-
nificantly higher (P
 0.05) proliferation than splenocytes from
the corresponding mixture groups. Similarly, for a given adju-
vant, splenocytes from the MSP-Fu24-immunized group
showed significantly higher levels of proliferation when stimu-
lated with the respective component antigens (PfMSP-119 and
PfMSP-311) than the groups immunized with the individual
antigen (see Table S1 in the supplemental material).
As shown in Table S2 in the supplemental material, MSP-
Fu24, PfMSP-119, PfMSP311, and the mixture formulated in
Montanide ISA720 elicited higher IFN- responses than the
respective alum formulation groups (P 
 0.05). For a given
adjuvant, splenocytes from the MSP-Fu24 group stimulated
with MSP-119 or MSP-311 showed IFN- secretion comparable
to the secretion by splenocytes from the MSP-119 or MSP-311
group, respectively, after stimulation with the respective anti-
gens. IFN- secretion was variable with physical mixture im-
munization groups; splenocytes from the mixture-Montanide
group showed IFN- secretion comparable to that of the
PfMSP-119–Montanide and PfMSP-311–Montanide groups.
However, the mixture-alum group showed lower levels of
IFN- compared to the PfMSP-119–alum and PfMSP-311–alum
groups (see Table S2 in the supplemental material).
Anti-MSP-Fu24 antibody recognizes the native parasite pro-
tein and conformation-specific epitopes in PfMSP-119. Affin-
ity-purified anti-MSP-Fu24 antibodies from all immunization
groups were assessed for their ability to recognize the native
parasite protein in the blood stage of P. falciparum 3D7 para-
FIG. 2. Reactivity of MSP-Fu24, PfMSp-119, and PfMSP-311 with
anti-PfMSP-1 conformation-specific MAb 12.1 and MAb 5.2 by ELISA
under nonreducing (Non-red) and reducing conditions. The assay for
the reactivity of each recombinant protein with anti-penta-His anti-
body was carried out in parallel as a positive control to ascertain an
equal amount of coating of the antigens under reducing and nonre-
ducing conditions.
FIG. 3. Immune response in groups of BALB/c mice immunized with MSP-Fu24, PfMSP119, PfMSP-311, or a mixture of PfMSP119 and
PfMSP-311 formulated in different adjuvants. End point titers for anti-PfMSP119, anti-PfMSP-311, and anti-MSP-Fu24 were determined by ELISA
using the respective capture antigens and mouse sera collected on day 70. The highest dilution of sera showing an OD greater than or equal to
the reactivity of the preimmune sera plus 2 SDs was considered to be the end point titer. Recombinant PfMSP-119 and PfMSP-311 were used as
the capture antigens to determine the immune response to the component antigens (PfMSP-119 and PfMSP-311) in the sera from group of mice
immunized with MSP-Fu24 or with a physical mixture of the two components.
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sites by immunofluorescence assay (IFA). Antibodies to MSP-
Fu24 showed strong reactivity on the surface of P. falciparum
merozoites. IFA end point titers varied from 1:40,000 to
1:8,0000; the highest antibody titers were observed for rabbit
and mouse sera immunized with MSP-Fu24 formulated in Mon-
tanide ISA720. Fluorescence staining with anti-MSP-Fu24 an-
tibody colocalized with the staining by anti-PfMSP-119 as well
as with anti-PfMSP-311 antibodies (Fig. 4). Similar results were
also obtained with purified IgG from mice and rabbits immu-
nized with a mixture of PfMSP-119 and PfMSP-311 (data not
shown).
Competitive ELISA was carried out to investigate if the
purified antibody from rabbit sera immunized with MSP-Fu24
contained conformation-specific and/or invasion- and processing-
inhibiting antibodies directed against PfMSP-119. As shown in
Fig. 5, purified anti-MSP-Fu24 antibodies inhibited the binding
of conformation-specific MAb 5.2 as well as invasion- and
processing-inhibitory MAb 12.10 with PfMSP-119 in a concen-
tration-dependent manner. An approximately 50% reduction
in the reactivity of MAb 5.2 was observed by competitive ELISA
with anti-MSP-Fu24 antibodies at a concentration of 0.3 g/ml;
similarly, anti-MSP-Fu24 at a concentration 0.15 g/ml caused
a 50% reduction in the reactivity of MAb 12.10 in this assay.
Thus, immunization with MSP-Fu24 induced conformation-
specific as well as invasion/processing-inhibitory antibodies.
In vitro parasite growth inhibition by anti-MSP-Fu24 anti-
bodies. Purified rabbit IgGs were assessed for their efficacy in
inhibiting in vitro parasite growth of P. falciparum strains 3D7
and FCR. Table 1 shows the percent invasion inhibition by
purified antibody from rabbits immunized with different anti-
gen-adjuvant formulations. Purified IgGs from sera of rabbits
immunized with MSP-Fu24 formulations showed up to 75%
and 66% parasite growth inhibitions of the 3D7 and FCR
parasite strains, respectively, in a dose-dependent manner. Pu-
rified antibodies from rabbits immunized with the mixture of
the two antigens also showed comparable invasion inhibition
levels for both the strains. To ascertain that specific antibodies
mediated this growth inhibition, antibodies specific to MSP-
Fu24, PfMSP-119, or PfMSP-311 were depleted from purified
anti-MSP-Fu24 rabbit antibodies by using different concentra-
tions of recombinant MSP-Fu24, PfMSP-119, and PfMSP-311,
respectively. These antibody samples depleted of specific IgGs
were then assessed for their efficacies in inhibiting P. falcip-
arum 3D7 parasite invasion. The depletion of anti-MSP-Fu24-
specific antibodies showed up to an 80% reversal in the growth
inhibition rate in a concentration-dependent manner, whereas
PfMSP-119-depleted antibody showed a 70% reversal (Fig.
6). However, PfMSP-311 showed only a 23% reversal in
growth inhibition at the same concentration. Recombinant
PfHRP-2, used as a negative control in a depletion assay, did
not show any reversal of invasion inhibition.
Anti-MSP-Fu24 antibodies inhibit parasite growth in an
ADCI assay. We investigated the efficacy of purified anti-MSP-
Fu24 mouse antibodies in inhibiting parasite growth in coop-
eration with monocytes in an ADCI assay. As shown in Fig. 7A,
IgGs purified from the MSP-Fu24–alum and MSP-Fu24–Mon-
tanide groups of mice significantly (P
 0.05) inhibited parasite
growth (SGI of up to 63%) in cooperation with monocytes in
a concentration-dependent manner. It was also observed that
the ADCI effect was dependent on the IgG concentration.
Purified IgG from mice immunized with a physical mixture of
the two antigens also inhibited parasite growth (SGI of up to
53%) in a similar manner. However, no significant differences
were observed between growth inhibition by IgGs from MSP-
Fu24 and mixture immunization groups for a given adjuvant
FIG. 4. Immunofluorescence assay with P. falciparum 3D7 para-
sites using anti-MSP-Fu24 antibodies. Shown are fluorescence and
bright-field images of acetone-methanol-fixed P. falciparum 3D7 par-
asites at the schizont stage immunostained with purified anti-MSP-
Fu24 (red) and anti-PfMSP-119 (green) or anti-MSP-311 (green) anti-
body. Parasite nuclei were stained with DAPI (blue).
FIG. 5. Inhibition of binding of conformation-dependent anti-
PfMSP119 MAb 12.10 (A) and MAb 5.2 (B) with recombinant PfMSP-
119 by purified anti-MSP-Fu24 antibodies. The reactivity of monoclonal
antibodies with PfMSP119 preincubated with different concentrations
of purified anti-MSP-Fu24 antibodies was assessed by use of a compet-
itive ELISA. The arrow indicates the concentration of anti-MSP-Fu24
antibodies that brings about a 50% decrease in reactivity. Antibodies
purified from preimmune sera were used as negative controls.
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(Fig. 7A). Similar levels of inhibition were observed with anti-
PfMSP-3 and anti-MSP-Fu24 antibodies; however, no signifi-
cant inhibition was observed using anti-PfMSP-119 antibodies.
To ascertain the specificity of growth inhibition, the anti-MSP-
Fu24 antibodies were depleted by using recombinant PfMSP-
119 or PfMSP-311. The depleted anti-MSP-Fu24 antibodies
were then used for ADCI assays. A reversal of growth inhibi-
tion was observed after the depletion of PfMSP-311-specific
antibodies (Fig. 7B), indicating that the observed ADCI effect
was mediated largely by the presence of antibodies specific to
PfMSP-311 in a fusion chimera.
DISCUSSION
It is generally believed that subunit vaccines containing more
than one malaria antigen will have more of a chance of success
than those based on a single antigen. The advantages of a
combination vaccine is the possibility of a simultaneous attack
on more than one parasite target and the countering of para-
site growth by different mechanisms. A combination vaccine
may also provide a synergetic response. However, such an
approach would necessarily require the development and anal-
ysis of individual components of the combination vaccine. Pro-
teins that appear on the surface of merozoites of P. falciparum
are considered possible candidates for blood-stage malaria
vaccines, and out of the many merozoite surface proteins iden-
tified so far, PfMSP-1 and PfMSP-3 are among the most prom-
ising vaccine candidate antigens. Interestingly, these two anti-
gens seem to generate protective immune responses by entirely
different mechanisms: while the antibody response to the C-
terminal fragments of PfMSP-1 is supposed to be invasion
inhibitory, the protective response of MSP-3 is believed to be
in a monocyte-dependent manner through ADCI (23, 28). In
the present study, we have produced a chimeric malaria pro-
tein containing the C-terminal fragment of PfMSP-119 fused
downstream with a conserved, immunologically relevant region
of PfMSP-3; in addition, we also produced the two individual
component polypeptides separately. The main aim of the study
was to compare immune responses of the fusion protein, MSP-
Fu24, with those of a mixture of its individual components
(PfMSP-119 and PfMSP-311) and also to assess the antiparasitic
TABLE 1. Inhibition of P. falciparum invasion of erythrocytes by purified antibodies from sera of rabbits immunized with MSP-Fu24 or with a
mixture of PfMSP-311 and PfMSP119 formulated with Montanide ISA720 or alum
a
Immunization group Parasite strain
% Parasitemiab (SD) at concn of IgG Ab (mg/ml) ofc: % Invasion inhibition
d at concn of IgG
Abs (mg/ml) of:
0.125 0.25 0.5 0.125 0.25 0.5
Preimmune 3D7 3.68 (0.75) 3.62 (0.34) 4.36 (0.33)
FCR 3.78 (0.07) 3.95 (0.14) 4.19 (0.05)
PfMSP142 3D7 2.01 (0.29) 2.18 (0.104) 1.61 (0.28) 45.4 39.78 63.0
FCR 2.36 (0.09) 2.25 (0.07) 1.74 (0.08) 37.57 43.04 58.47
MSP-Fu24-Montanide 3D7 1.9 (0.08) 1.77 (0.44) 1.37 (0.05) 48.36 51.7 68.6
FCR 2.07 (0.07) 1.98 (0.15) 1.52 (0.03) 45.24 49.87 63.80
MSP-Fu24-alum 3D7 1.94 (0.43) 1.45 (0.12) 1.11 (0.14) 47.28 59.94 74.5
FCR 2.53 (0.07) 2.3 (0.08) 1.39 (0.08) 32.98 41.77 66.83
Mixture-Montanide 3D7 2.38 (0.07) 2.37 (0.35) 1.97 (0.33) 35.32 34.5 54.81
FCR 3.22 (0.09) 2.7 (0.09) 2.01 (0.14) 14.81 31.65 51.95
Mixture-alum 3D7 2.37 (0.31) 2.16 (0.45) 2.31 (0.35) 35.6 40.1 47.0
FCR 3.42 (0.16) 2.38 (0.09) 2.05 (0.13) 9.44 39.58 51.07
a Anti-PfMSP-142 rabbit antibodies were used as a control.
b Parasitemia values are the averages of triplicate determinations.
c Final concentration of IgG in a well.
d Calculated against the respective preimmune Ab well. The proportion of parasitized red blood cells in test wells was statistically significantly high compared to those
in the respective control wells (P  0.005 by chi-square test).
FIG. 6. Reversal of anti-MSP-Fu24 antibody-mediated inhibition of P.
falciparum invasion after depletion of antigen-specific antibodies. The
invasion inhibition by anti-MSP-Fu24 antibodies (250 g/ml) was assessed
after the preincubation of antibodies with different amount of recombi-
nant MSP-Fu24, PfMSP119, or PfMSP-311 to deplete antibodies specific to
the respective antigens. PfHRP-2 was also used as one of the antigens for
antibody depletion in the assay as a negative control. The percent reversal
of invasion inhibition was calculated based upon invasion inhibition with-
out any antibody depletion.
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efficacies induced by the immune responses generated. The
three recombinant proteins were expressed in E. coli cells,
purified to homogeneity, and characterized by different stan-
dard procedures.
For a number of merozoite surface proteins that are rich in
cysteine residues, the generation of parasite-inhibitory anti-
bodies is dependent on specific protein conformations stabi-
lized by several disulfide linkages, which makes it critical to
produce such vaccine target recombinant proteins that confor-
mationally resemble their native counterparts (5, 17, 26, 45).
PfMSP-119 is highly structured, contains six disulfide linkages,
and folds into two epidermal growth factor-like domains,
which provide it with conformational stability (8, 26). A num-
ber of MAbs that show reactivity with PfMSP-119 only when it
attains an appropriate conformation have been developed
(45). Our results of immunoblotting and ELISA using different
conformation-dependent MAbs showed that MSP-Fu24 con-
tained immunologically relevant conformational epitopes of
PfMSP-119, suggesting that the MSP-119 component in MSP-
Fu24 has acquired a conformation similar to that of the native
protein. The complete loss of reactivity of the conformational
MAbs with the fusion protein under reducing conditions indi-
cated that the tertiary structure of the protein is stabilized by
disulfide linkages. Furthermore, MSP-Fu24 was recognized by
the majority of sera from individuals residing in an area where
malaria is endemic, indicating that it contained an epitope(s)
present in its component antigens that may be the targets of
the antibody response generated during natural exposure to P.
falciparum. In addition, anti-MSP-Fu24 antibodies recognized
both native PfMSP-1 and PfMSP-3 on the parasite surface.
We tested the immunogenicities of MSP-Fu24 and a physical
mixture of its two-component antigens using three different
adjuvants, alum, Montanide ISA720, and CFA/IFA, in small
animals. Two of these adjuvants, alum and Montanide ISA720,
were used previously in malaria vaccine trials for monkeys as
well as humans (11, 14, 21, 37). We found that immunization
with MSP-Fu24 induced a significant antibody response with all
three adjuvant formulations. Considering that most vaccine
target malaria recombinant antigens are poorly immunogenic,
the high antibody response to the fusion protein in alum and
Montanide ISA720 is encouraging. Antigenic competition or
immunodominance of individual component antigens could be
a potential hindrance in the development of combination-an-
tigen-based vaccines. Immunization with MSP-Fu24 in different
adjuvant formulations elicited an immune response to each of
its components that was comparable to that induced by immu-
nization with individual components. These results suggested a
lack of antigenic competition when the two antigens were pre-
sented together as a fusion protein or as a physical mixture of
the two. Such a lack of antigenic competition was observed
previously by workers using other combination malaria vaccine
constructs. For example, no antigenic competition was ob-
served for studies with PfCP 2.9, a fusion chimera of PfMSP-
119 and PfAMA-1 (31), or when this fusion protein was ad-
ministered in combination with another recombinant antigen,
PfEBA-175 (F2), as a single formulation (47). Similar obser-
vations were made when the C-terminal region of the PfCSP,
including the repeats, was administered in combination with
PfCP 2.9 (48). In another study, a fusion construct of P. yoelii
MSP-1 and MSP-8 also induced an antibody response compa-
rable to that of the two components (38). It appears that the
immunodominant regions of the malaria proteins selected in
these studies and in the present one have inherently strong
structural preferences, which are maintained when they are
presented in fusion chimeras.
The recombinant fusion chimera stimulated T lymphocytes
in an in vitro assay with various stimulation indices depending
on the adjuvant used. In general, the level of splenocyte pro-
liferation was higher in MSP-Fu24-immunized groups than in
the physical mixture groups. Cytokines play an important role
in determining the IgG subclass. IFN- is a product of Th1
cells and is generally associated with the production of IgG2a,
also an indicator of cell-mediated immunity. The production of
IFN- and IgG subtype analysis of the immune response indi-
cated that both Th1 and Th2 subsets of T-helper cells are
elicited by the fusion protein.
Although many adjuvant formulations have been shown to
FIG. 7. (A) Specific growth inhibition (SGI) index of antibody-depen-
dent cellular inhibition (ADCI) of parasite growth by total IgG purified from
sera of mice immunized with MSP-Fu24, PfMSP119, PfMSP-311, or a mixture
of PfMSP119 and PfMSP-311 formulated in Montanide ISA720 or alum.
Parasites at the schizont stage were cocultured with human monocytes in the
presence of purified antibodies (50g/ml of culture in the assay), and parasite
growth was monitored after 96 h. (B) Reversal of antibody-dependent cellular
inhibition of parasite growth by depletion of antigen-specific antibodies. The
SGI index of ADCI of parasite growth purified from sera of mice immunized
with MSP-Fu24–Montanide after incubation of antibodies with recombinant
MSP-Fu24, PfMSP119, or PfMSP-311 to deplete antibodies specific to the
respective antigen was determined.
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induce high-titer antibodies against malarial antigens, it was
also shown that the antibody titers alone are not sufficient to
ensure protection, even when the antigen contained protective
epitopes (19); the kind of antibody response generated by
synthetic immunogens is equally important. Particularly for
PfMSP-119, several studies have shown that it was not the total
antibody titers but the levels of specific invasion-inhibitory and
processing-inhibitory antibodies that correlated with protec-
tion (9, 12, 20, 30, 45). Therefore, it was important to deter-
mine the fine specificity of anti-PfMSP-119 antibody induced by
the fusion chimera that may be indicative of its antiparasitic
efficacy. Of several MAbs (5.2, IE1, 12.10, 2F10, 111.4, and
12.8) raised against PfMSP-1, MAbs 5.2, 2F10, 12.10, and 12.8
have been shown to be directed against conformation-specific
epitopes of PfMSP-119. In addition, MAbs 12.10 and 12.8 also
inhibit the proteolytic processing of PfMSP-1 during merozoite
invasion (1, 7, 13). We carried out a competition ELISA-based
analysis of mouse immune sera to assess the presence of anti-
MSP-Fu24 antibodies that share a conformation-specific epitope(s)
with these invasion/processing-inhibitory MAbs. The degree of
competition in this assay is influenced mainly by the relative
affinities of serum antibodies and the MAbs, the degree of
overlap of the epitopes, and the concentration of serum anti-
bodies. Similar assays were used previously to assess the in-
duction of PfMSP-119-specific invasion-inhibitory antibodies
against immunization of mice/rabbits with PfMSP-142 formu-
lations (36). Our results show that immunization with MSP-
Fu24 elicited antibodies against the PfMSP-119 component that
share epitopes with conformation-specific and invasion/pro-
cessing-inhibiting MAbs; these results also suggest that MSP-
Fu24 can induce invasion-inhibitory/processing antibodies when
used as an immunogen with human-compatible adjuvants.
In the absence of any direct correlates of protection against
malaria, in vitro assays such as invasion inhibition and ADCI
assays are used to assess the antiparasitic efficacy of the im-
mune response generated to an immunogen (11, 36, 39, 40, 46).
We found that purified Abs from sera of rabbits immunized
with MSP-Fu24 strongly inhibited the parasite invasion of not
only homologous P. falciparum strain 3D7 but also strain FCR.
Furthermore, the depletion of MSP-Fu24- and PfMSP-119-spe-
cific antibodies from total anti-MSP-Fu24 antibodies decreased
this inhibition, indicating the specificity of the invasion inhibi-
tion assay. On the other hand, the depletion of PfMSP-3-
specific antibodies did not cause any significant reduction in
invasion inhibition, suggesting that the antibody response directed
against the MSP-119 component in MSP-Fu24 was mainly respon-
sible for the invasion inhibition.
It was previously shown that some merozoite surface pro-
teins, such as PfMSP-3, PfMSP-6, and PfGLURP, provide
ADCI-mediated protection against the parasite compared to
the direct invasion inhibition by PfMSP-1 (28, 29, 40, 42). For
ADCI of malaria parasites, the antibodies against these pro-
teins act in cooperation with host monocytes. These anti-
bodies form a complex with the respective merozoite pro-
teins and then interact with FcRIIA on the monocytes,
which induces the release of killing factors such as tumor
necrosis factor alpha (TNF-) (3). The human FcIIa re-
ceptor is the primary trigger molecule for ADCI and exists
in two alloforms, FcRIIA-Arg/Arg131 and FcRIIA-His/
His131 (4, 32). Mouse IgG1 and IgG2b isotype antibodies bind
well with the more prevalent FcIIa receptor FcRIIA-Arg/
Arg131 (33). Our results showed that anti-MSP-Fu24 antibodies
from the alum and Montanide ISA720 immunization groups
significantly inhibited parasite growth in a dose-dependent
manner in the ADCI assay. The ADCI-mediated parasite
growth inhibition by anti-MSP-Fu24 antibodies was compara-
ble to that by the antibodies induced by a mixture of the two
component antigens. Furthermore, the depletion of anti-
PfMSP-311 antibodies decreased the level of parasite growth
inhibition, suggesting that anti-MSP-Fu24 antibodies directed
against PfMSP-311 contribute to the protective immune re-
sponse against the parasite through ADCI-related mecha-
nisms. Although the heterogeneous combination of mouse an-
tibodies with human monocytes in these assays may not be
entirely satisfactory or close to the natural conditions, it is not
possible to generate anti-MSP-Fu24 antibodies in humans for
these assays in the present study. Therefore, to assess the
efficacy of antibodies induced by the recombinant antigen
MSP-Fu24, to elicit ADCI, we have used mouse antibodies with
human monocytes as the next-best approximation for these in
vitro assays. It may be important that such a heterogeneous
combination was used previously for a similar set of ADCI
experiments (42).
The multivalent vaccine concept is an attractive strategy for
the development of a malaria vaccine, even though each of the
component antigens of such a vaccine would need to be devel-
oped separately. The use of a fusion protein consisting of the
immunodominant region from different antigens may provide
a feasible alternative strategy. In this study, we generated a
fusion protein, MSP-Fu24, consisting of immunodominant re-
gions of PfMSP-3 and PfMSP-1. A simple protocol was estab-
lished to express MSP-Fu24 as a soluble protein in relatively
high yields, which can be easily scaled up for large-scale pro-
duction under cyclic GMP (cGMP) conditions. Given that it
has not been easy to produce PfMSP-119 as a soluble protein
with satisfactory yields, it is quite remarkable that its fusion
with a specific fragment of PfMSP-3 has resulted in an easy-
to-purify fusion protein with the appropriate folding of the
PfMSP-119 component. The fusion protein formulated with
human-compatible adjuvants is highly immunogenic in small
animals, and the two-component polypeptides have maintained
their functional identity in the context of the immune response to
the fusion protein. Our data suggest that the fusion protein has
the potential to be developed as a malaria vaccine candidate.
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